相关实验视频

Updated: May 8, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

编码pri-miR-375的创新的小圆形DNA载体在HPV16阳性CaSki细胞中沉默E6和E7上蛋白

D Pereira¹, A M Almeida², J A Queiroz²

¹RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; CDRSP-PL-Centre for Rapid and Sustainable Product Development, Polytechnic of Leiria, Marinha Grande, 2430-028 Leiria, Portugal.

|December 19, 2025

概括

使用提供微RNA-375 (miR-375) 的微圆DNA (mcDNA) 载体的基因治疗有效地使宫癌细胞中的人类乳头瘤病毒 (HPV) E6/E7 上蛋白沉默. 这种方法为治疗与HPV相关的宫癌提供了一个有希望的新途径.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因治疗基因治疗

背景情况:

人类乳头瘤病毒 (HPV) 感染,特别是高风险型HPV16/18,是导致子宫癌的主要原因.
HPV 型蛋白 E6/E7 抑制了关键的瘤抑制蛋白 p53 和 pRB.
微RNA-375 (miR-375) 在宫癌中下调,并准HPV E6/E7转录.

研究的目的:

开发和评估使用小圆DNA (mcDNA) 载体的基因疗法策略,以提供pri-miR-375用于宫癌治疗.
评估mcDNA-pri-miR-375能够使HPV E6/E7coproteins沉默并抑制癌细胞增殖和入侵的能力.

主要方法:

构建和净化 mcDNA-pri-miR-375 载体.
在实验室中,CaSki细胞 (HPV16感染的宫癌模型) 与载体感染.
对焦显微镜,RT-PCR,RT-qPCR和西部斑点分析以评估基因和蛋白质表达.
细胞增殖,入侵和活力测试.

主要成果:

mcDNA-pri-miR-375成功地定位到癌细胞的核中.
显著的减少 (大约. 80%) 在HPV E6/E7转录和蛋白质水平观察到感染后24小时.
抑制CaSki细胞的增殖和侵入,在72小时内细胞活力下降.
恢复p53蛋白水平和增加caspase-3活性,表明诱导了亡.

结论:

mcDNA-pri-miR-375载体显示出作为HPV相关子宫癌的治疗剂的显著潜力.
基因疗法方法有效地准和沉默HPVcoproteins,从而产生抗癌效应.
需要进一步的研究来探索这种新型基因治疗策略的临床适用性.

关键词:

宫癌是发生在宫癌的原因之一.基因治疗是一种基因疗法.人类乳头瘤病毒的人类乳头瘤病毒迷你圆形DNA是什么意思在 miR-37575 里面.

更多相关视频

Production of Double-stranded DNA Ministrings

Production of Double-stranded DNA Ministrings

Published on: February 29, 2016

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...